Kura Oncology, Inc. (KURA)
| Market Cap | 783.77M |
| Revenue (ttm) | 67.48M |
| Net Income (ttm) | -278.67M |
| Shares Out | 88.76M |
| EPS (ttm) | -3.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,182,304 |
| Open | 9.07 |
| Previous Close | 9.07 |
| Day's Range | 8.75 - 9.20 |
| 52-Week Range | 5.45 - 12.49 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | 25.56 (+189.47%) |
| Earnings Date | Apr 30, 2026 |
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional n... [Read more]
Financial Performance
In 2025, Kura Oncology's revenue was $67.48 million, an increase of 25.24% compared to the previous year's $53.88 million. Losses were -$278.67 million, 60.2% more than in 2024.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for KURA stock is "Buy." The 12-month stock price target is $25.56, which is an increase of 189.47% from the latest price.
News
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
– Regulatory Filing in Japan Planned Following Clinical Trial Completion – – Regulatory Filing in Japan Planned Following Clinical Trial Completion –
Kura Oncology Advances Kidney Cancer Program With Solid Early-Stage Results
The FIT-001 study is evaluating darlifarnib (KO-2806) in patients with RCC at once-daily doses of 3 mg, 5 mg, or 8 mg alternating 7 days on and off in combination with cabozantinib at once-daily doses...
Kura Oncology Transcript: Investor Update
Updated Phase 1 data show darlifarnib plus cabozantinib achieves a 44% objective response rate and 94% disease control in heavily pretreated, cabozantinib-refractory RCC patients, with a favorable safety profile. Expansion into cabozantinib-naive patients and broader solid tumor combinations is underway.
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026
Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatmen...
Kura Oncology Transcript: Barclays 28th Annual Global Healthcare Conference
Komzifti's launch is exceeding expectations with strong payer uptake and positive KOL feedback. Ziftomenib's development is advancing with streamlined global trials and upcoming data updates, while tipifarnib combinations target resistance in KRAS and RCC with promising safety and efficacy.
Kura Oncology Transcript: Leerink Global Healthcare Conference 2026
KOMZIFTI's launch has achieved rapid market access and strong initial sales, with ambitions to lead the NPM1 mutant AML market and expand into larger frontline opportunities. Multiple clinical data readouts for ziftomenib and darlifarnib are expected this year, supported by a robust cash position and strategic partnerships.
Kura Oncology Earnings Call Transcript: Q4 2025
2025 saw a successful Komzifti launch with $2.1M in revenue, rapid payer adoption, and strong clinical feedback. The company is advancing a broad AML and solid tumor pipeline, with robust cash reserves and multiple catalysts expected in 2026.
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
– KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, ...
Kura Oncology Transcript: TD Cowen 46th Annual Health Care Conference
2026 is set as a key inflection year, with Komzifti's commercial launch in NPM1-mutated AML showing strong early uptake and differentiation. Multiple phase III trials, combination regimens, and expansion into solid tumors and metabolic diseases are underway, supported by a robust cash position.
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, toda...
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, toda...
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
– Launched KOMZIFTI ™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million KOMZIFTI net product revenue for the period from firs...
Kura Oncology Transcript: Status Update
Ziftomenib in combination with azacitidine and venetoclax demonstrated high response and MRD negativity rates in both newly diagnosed and relapsed/refractory NPM1-mutated AML, with a favorable safety profile and minimal added toxicity. Ongoing phase 3 trials and additional combination studies aim to expand its clinical utility and support broader adoption.
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and ove...
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, toda...
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of canc...
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated AML, is now commercially available in the United States KOMZIFTI, the first and only once-daily FDA-approved m...
Kura Oncology Transcript: Jefferies London Healthcare Conference 2025
FDA approval for a novel menin inhibitor in relapsed/refractory AML with NPM1 mutation highlights strong efficacy, superior safety, and convenient dosing. Market potential is significant, with ongoing trials targeting both frontline and maintenance settings.
Kura Oncology Transcript: FDA Announcement
FDA approved KOMZIFTI (ziftomenib) for relapsed/refractory NPM1-mutated AML, citing strong efficacy, a favorable safety profile, and no significant drug-drug interactions. The launch is underway with a $48,500/month price, and ongoing trials aim to expand its use across AML settings.
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
– NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R NPM1-mutated AML defined by historically poor outcomes and low survival rat...
US FDA approves Kura Oncology's blood cancer therapy
The U.S. Food and Drug Administration has approved Kura Oncology's drug to treat a rare form of blood cancer that has returned or resisted initial therapy, the regulator said on Thursday.
Kura Oncology to Participate in Upcoming Investor Conference
SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Kura Oncology Earnings Call Transcript: Q3 2025
Clinical and commercial progress for Zifduminib continues, with strong clinical data, robust financials, and launch readiness ahead of the November 2025 PDUFA date. Cash reserves and milestone payments support operations through 2027, while the FTI pipeline advances in parallel.